pegylated liposomal doxorubicin (PLD) + cyclophosphamide (C) + trastuzumab (H) + pertuzumab (P) + docetaxel (T) + docetaxel (T) + carboplatin (Cb) + trastuzumab (H) + pertuzumab (P)
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Dec 20, 2021 → Jan 31, 2028
NCT ID
NCT05159193About pegylated liposomal doxorubicin (PLD) + cyclophosphamide (C) + trastuzumab (H) + pertuzumab (P) + docetaxel (T) + docetaxel (T) + carboplatin (Cb) + trastuzumab (H) + pertuzumab (P)
pegylated liposomal doxorubicin (PLD) + cyclophosphamide (C) + trastuzumab (H) + pertuzumab (P) + docetaxel (T) + docetaxel (T) + carboplatin (Cb) + trastuzumab (H) + pertuzumab (P) is a phase 3 stage product being developed by Sun Pharmaceutical for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05159193. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05159193 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Cancer